Bicycle Therapeutics plc (NASDAQ:BCYC) is pioneering the way forward in a new and differentiated class of therapeutics based on its bicycle peptide technology. On June 20th, 2023 at 12:30 p.m. ET, company executives will participate in a fireside chat at the TD Cowen Radiopharmaceutical Innovation Summit, offering an insightful introduction to the groundbreaking development made possible by this pioneering technology. Tune in to the virtual event for an inside look at the potential of this pioneering science.
About Bicycle Therapeutics
Bicycle Therapeutics (NASDAQ: BCYC) is leading the way in the development of a groundbreaking new class of medicines known as Bicycles. These groundbreaking molecules are designed to help treat disease through a far more precise approach than we have seen before. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds, resulting in two distinct loops that provide them with remarkable levels of structural stability and target binding, making them ideal drug candidates for those conditions where existing treatment options have failed.